Top

Review Article

JKDA 2020; 3(1): 9-11

Published online May 25, 2020

© Korean Society of Dialysis Access

동정맥루 수술 후 개통성 향상을 위한 약물 치료

전흥만

인제대학교 일산백병원 외과

Received: March 28, 2020; Revised: April 3, 2020; Accepted: April 28, 2020

Medical Adjuvant Treatment for Improving Patency After Arteriovenous Fistula

Heungman Jun

Department of Surgery, Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Korea

Correspondence to : 전흥만
우 10380, 고양시 일산서구 주화로 170, 인제대학교 일산백병원 외과
Tel: 031-910-7947, Fax: 031-910-7782, E-mail: junh@paik.ac.kr

Received: March 28, 2020; Revised: April 3, 2020; Accepted: April 28, 2020

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Many patients who use hemodialysis for end-stage renal disease (ESRD) require arteriovenous fistula (AVF). There have been many efforts including preoperative and postoperative access surveillance to improve the primary patency after AVF. Several drugs have been proposed to improve AVF patency based on anticoagulants, antiplatelets or antihypertensives. However, there is little evidence to guide the drug strategy. This review did not show a beneficial effect on the treatment of any adjuvant that increases the patency of AVF, except for ticlopidine and calcium channel blockers.

Keywords Medical adjuvant treatment, Arteriovenous fistula, Patency

Article

Review Article

JKDA 2020; 3(1): 9-11

Published online May 25, 2020

Copyright © Korean Society of Dialysis Access.

동정맥루 수술 후 개통성 향상을 위한 약물 치료

전흥만

인제대학교 일산백병원 외과

Received: March 28, 2020; Revised: April 3, 2020; Accepted: April 28, 2020

Medical Adjuvant Treatment for Improving Patency After Arteriovenous Fistula

Heungman Jun

Department of Surgery, Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Korea

Correspondence to:전흥만
우 10380, 고양시 일산서구 주화로 170, 인제대학교 일산백병원 외과
Tel: 031-910-7947, Fax: 031-910-7782, E-mail: junh@paik.ac.kr

Received: March 28, 2020; Revised: April 3, 2020; Accepted: April 28, 2020

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Many patients who use hemodialysis for end-stage renal disease (ESRD) require arteriovenous fistula (AVF). There have been many efforts including preoperative and postoperative access surveillance to improve the primary patency after AVF. Several drugs have been proposed to improve AVF patency based on anticoagulants, antiplatelets or antihypertensives. However, there is little evidence to guide the drug strategy. This review did not show a beneficial effect on the treatment of any adjuvant that increases the patency of AVF, except for ticlopidine and calcium channel blockers.

Keywords: Medical adjuvant treatment, Arteriovenous fistula, Patency

Journal of Korean Dialysis Access

eISSN 2635-8603
qr-code Download